Breaking News Instant updates and real-time market news.

2018-02-13 07:05:50

ICPT

Intercept

$54.63

0.42 (0.77%)

07:05

02/13/18

02/13

07:05

02/13/18

07:05

Intercept price target lowered to $57 from $62 at Wells Fargo

Wells Fargo analyst Jim Birchenough lowered his price target for Intercept to $57 from $62 following his most recent review of the FDA AERS Safety Database for marketed bile acid analog OCALIVA, and significant increase in patient deaths in Q4. While Intercept has highlighted an independent safety review of post-marketing safety events cited in a September, 2017 FDA Drug Safety Communication, the analyst believes that significant increase in patient deaths in Q4 is concerning and the rate is above that predicted for the approved OCALIVA patient population by his estimate. Birchenough reiterates a Market Perform rating on the shares.

14

Feb

21

Feb

12

Mar

ICPTIntercept

$54.63

0.42 (0.77%)

02/07/18

GSCO

02/07/18DOWNGRADETarget $45GSCOSell

Intercept downgraded to Sell from Neutral at Goldman Sachs

Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell and cut his price target for the shares to $45 from $74. The analyst sees a lack of catalyats to move the stock higher. Intercept closed yesterday up $2.08 to $60.82.

02/12/18

DBAB

02/12/18NO CHANGETarget $103DBABBuy

Intercept study initiation a positive, says Deutsche Bank

Deutsche Bank analyst Navin Jacob views the initiation of the Reverse NASH trial is a positive for Intercept Pharmaceuticals, saying it "puts to rest any lingering bear arguments that OCA is not safe." The trial, if successful, presents potential upside to numbers, Jacob tells investors in a research note. He keeps a Buy rating on the shares with a $103 price target.

02/02/18

DBAB

02/02/18NO CHANGETarget $103DBABBuy

Intercept label update is best case scenario, says Deutsche Bank

Deutsche Bank analyst Navin Jacob says the updated label for Intercept Pharmaceuticals' Ocaliva is not just a good case, it is the best case. The black box warning and lack of restrictions in any patient population is a "big positive surprise," Jacob tells investors in a research note. The monitoring appears to be a "complete non-issue" as it is likely only once every three-to-six months, the analyst adds. He trimmed his price target for the shares to $103 from $106 and keeps a Buy rating on Intercept.

02/01/18

COWN

02/01/18NO CHANGETarget $112COWNOutperform

Intercept label update should temper concerns, says Cowen

Cowen analyst Ritu Baral said the Black Box warning addition to Ocaliva's label was in-line with expectations, noting also that there was no mention of safety concern in mild PBC. Baral, who expects the update to temper concerns and stabilize Ocaliva sales, keeps an Outperform rating and $112 price target on Intercept Pharmaceuticals.

Nuance has ceased development this month of the Swype feature for both iOS and Android, six years after it acquired the company behind the keyboard app for roughly $100M, the Verge reports, citing an emailed statement. Nuance said that it would discontinue support of the keyboard app and shift focus to other products, the report says. "The core technology behind Swype will continue to be utilized and improved upon across other Nuance offerings - and integrated into our broader AI-powered solutions - most notably in Android-based keyboard solutions for our automotive customers," the company said, according to the Verge. Reference Link

Baskin-Robbins, a Dunkin' Brands company, announced its continued expansion in the Toronto, Ontario market with the signing of four new store development agreements with three existing franchise groups. The first Baskin-Robbins shop under these new agreements is scheduled to open in 2019. Currently, there are more than 80 Baskin-Robbins locations throughout the greater Toronto area, and growing the brand there remains a top priority for Baskin-Robbins in 2018 and beyond.

Reports Q4 revenue $369.0M, consensus $340.56M. Q4 Adjusted EBITDA was $110.5M for the three months ended December 31, 2017, up 294% sequentially from $28.0M for the three months ended September 30, 2017 and up 691% from $14.0M for the three months ended December 31, 2016.

UP AFTER EARNINGS: Bandwidth (BAND), up 12%... Avis Budget (CAR), up 8.3%... Mindbody (MB), up 8%... SailPoint Technologies (SAIL), up 7.1%... Stamps.com (STMP), up 6.5%... Gulfport Energy (GPOR), up 5.8%... Synopsys (SNPS), up 4.4%... Parsley Energy (PE), up 3.5%... Pandora (P), up 2.5%. ALSO HIGHER: Mellanox Technologies (MLNX), up 10.4% after it updated its first quarter outlook and announced that CFO Jacob Shulman is stepping down. DOWN AFTER EARNINGS: Roku (ROKU), down 22%... Applied Optoelectronics (AAOI), down 12.5%... Stericycle (SRCL), down 9.2%... Castlight Health (CSLT), down 9.1%... Ultra Clean (UCTT), down 8.3%... Trinity Industries (TRN), down 5.6%... Sturm, Ruger (RGR), down 4.9%... CyrusOne (CONE), down 1.7%. ALSO LOWER: Advaxis (ADXS), down 13.2% after it announced a common stock offering... GW Pharmaceuticals (GWPH), down 5.5% after it said that its Phase 2a study of GWP42006 did not meet its primary endpoint... OneMain Holdings (OMF), down 2% after it announced an offering of 4.18M shares of common stock for holders.